Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
Add more filters










Database
Language
Publication year range
1.
Br J Pharmacol ; 171(15): 3666-79, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24712707

ABSTRACT

BACKGROUND AND PURPOSE: The antipyretic and hypothermic prodrug dipyrone prevents PGE2 -dependent and -independent fever induced by LPS from Escherichia coli and Tityus serrulatus venom (Tsv) respectively. We aimed to identify the dipyrone metabolites responsible for the antipyretic and hypothermic effects. EXPERIMENTAL APPROACH: Male Wistar rats were treated i.p. with indomethacin (2 mg·kg(-1) ), dipyrone, 4-methylaminoantipyrine (4-MAA), 4-aminoantipyrine (4-AA) (60-360 mg·kg(-1) ), 4-formylaminoantipyrine, 4-acethylaminoantipyrine (120-360 mg·kg(-1) ) or vehicle 30 min before i.p. injection of LPS (50 µg·kg(-1) ), Tsv (150 µg·kg(-1) ) or saline. Rectal temperatures were measured by tele-thermometry and dipyrone metabolite concentrations determined in the plasma, CSF and hypothalamus by LC-MS/MS. PGE2 concentrations were determined in the CSF and hypothalamus by elisa. KEY RESULTS: In contrast to LPS, Tsv-induced fever was not followed by increased PGE2 in the CSF or hypothalamus. The antipyretic time-course of 4-MAA and 4-AA on LPS-induced fever overlapped with the period of the highest concentrations of 4-MAA and 4-AA in the hypothalamus, CSF and plasma. These metabolites reduced LPS-induced fever and the PGE2 increase in the plasma, CSF and hypothalamus. Only 4-MAA inhibited Tsv-induced fever. The higher doses of dipyrone and 4-MAA also induced hypothermia. CONCLUSIONS AND IMPLICATIONS: The presence of 4-MAA and 4-AA in the CSF and hypothalamus was associated with PGE2 synthesis inhibition and a decrease in LPS-induced fever. 4-MAA was also shown to be an antipyretic metabolite for PGE2 -independent fever induced by Tsv suggesting that it is responsible for the additional antipyretic mechanism of dipyrone. Moreover, 4-MAA is the hypothermic metabolite of dipyrone.


Subject(s)
Ampyrone/pharmacology , Dinoprostone/metabolism , Dipyrone/analogs & derivatives , Fever/drug therapy , Ampyrone/blood , Ampyrone/cerebrospinal fluid , Ampyrone/metabolism , Animals , Antipyretics/blood , Antipyretics/cerebrospinal fluid , Antipyretics/pharmacokinetics , Antipyretics/pharmacology , Body Temperature/drug effects , Dinoprostone/cerebrospinal fluid , Dipyrone/blood , Dipyrone/cerebrospinal fluid , Dipyrone/metabolism , Dipyrone/pharmacokinetics , Dipyrone/pharmacology , Fever/chemically induced , Fever/metabolism , Hypothalamus/drug effects , Hypothalamus/metabolism , Hypothermia/chemically induced , Hypothermia/metabolism , Indomethacin/pharmacology , Lipopolysaccharides , Male , Prodrugs/pharmacokinetics , Rats, Wistar , Scorpion Venoms
2.
Bioanalysis ; 5(21): 2631-45, 2013 Nov.
Article in English | MEDLINE | ID: mdl-24180504

ABSTRACT

BACKGROUND: After oral administration dipyrone is rapidly hydrolyzed to 4-methylaminoantipyrine, which is absorbed and further metabolized to 4-formylaminoantipyrine and to 4-aminoantipyrine, which is acetylated by a polymorphic N-acetyltransferase system to 4-acetylaminoantipyrine. To evaluate the presence of dipyrone metabolites in different rat matrices after intraperitoneal administration, an analytical method was developed and validated. METHODOLOGY: The four main dipyrone metabolites were extracted from plasma, cerebrospinal fluid and hypothalamus samples by LLE prior to LC-MS/MS. RESULTS: Standard calibration graphs for all metabolites were linear (r > 0.99). The intra- and inter-day precision and accuracy values were both inferior to 15%. CONCLUSION: This method is simple and specific for studying dipyrone metabolites after intraperitoneal administration.


Subject(s)
Chromatography, High Pressure Liquid/methods , Dipyrone/analysis , Hypothalamus/chemistry , Tandem Mass Spectrometry/methods , Animals , Dipyrone/blood , Dipyrone/cerebrospinal fluid , Dipyrone/metabolism , Hypothalamus/metabolism , Male , Rats , Rats, Wistar
3.
Basic Clin Pharmacol Toxicol ; 110(4): 359-69, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22059515

ABSTRACT

The fact that there is a complex and bidirectional communication between the immune and nervous systems has been well demonstrated. Lipopolysaccharide (LPS), a component of gram-negative bacteria, is widely used to systematically stimulate the immune system and generate profound physiological and behavioural changes, also known as 'sickness behaviour' (e.g. anhedonia, lethargy, loss of appetite, anxiety, sleepiness). Different ethological tools have been used to analyse the behavioural modifications induced by LPS; however, many researchers analysed only individual tests, a single LPS dose or a unique ethological parameter, thus leading to disagreements regarding the data. In the present study, we investigated the effects of different doses of LPS (10, 50, 200 and 500 µg/kg, i.p.) in young male Wistar rats (weighing 180-200 g; 8-9 weeks old) on the ethological and spatiotemporal parameters of the elevated plus maze, light-dark box, elevated T maze, open-field tests and emission of ultrasound vocalizations. There was a dose-dependent increase in anxiety-like behaviours caused by LPS, forming an inverted U curve peaked at LPS 200 µg/kg dose. However, these anxiety-like behaviours were detected only by complementary ethological analysis (stretching, grooming, immobility responses and alarm calls), and these reactions seem to be a very sensitive tool in assessing the first signs of sickness behaviour. In summary, the present work clearly showed that there are resting and alertness reactions induced by opposite neuroimmune mechanisms (neuroimmune bias) that could lead to anxiety behaviours, suggesting that misunderstanding data could occur when only few ethological variables or single doses of LPS are analysed. Finally, it is hypothesized that this bias is an evolutionary tool that increases animals' security while the body recovers from a systemic infection.


Subject(s)
Anxiety/physiopathology , Behavior, Animal , Fear , Lipopolysaccharides/toxicity , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Exploratory Behavior , Lipopolysaccharides/administration & dosage , Male , Maze Learning , Rats , Rats, Wistar , Vocalization, Animal
4.
Br J Pharmacol ; 162(6): 1401-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21133897

ABSTRACT

BACKGROUND AND PURPOSE: Bacterial lipopolysaccharide (LPS) induces fever through two parallel pathways; one, prostaglandin (PG)-dependent and the other, PG-independent and involving endothelin-1 (ET-1). For a better understanding of the mechanisms by which dipyrone exerts antipyresis, we have investigated its effects on fever and changes in PGE(2) content in plasma, CSF and hypothalamus induced by either LPS or ET-1. EXPERIMENTAL APPROACH: Rats were given (i.p.) dipyrone (120 mg·kg(-1)) or indomethacin (2 mg·kg(-1)) 30 min before injection of LPS (5 µg·kg(-1), i.v.) or ET-1 (1 pmol, i.c.v.). Rectal temperature was measured by tele-thermometry. PGE(2) levels were determined in the plasma, CSF and hypothalamus by elisa. KEY RESULTS: LPS or ET-1 induced fever and increased CSF and hypothalamic PGE(2) levels. Two hours after LPS, indomethacin reduced CSF and hypothalamic PGE(2) but did not inhibit fever, while at 3 h it reduced all three parameters. Three hours after ET-1, indomethacin inhibited the increase in CSF and hypothalamic PGE(2) levels but did not affect fever. Dipyrone abolished both the fever and the increased CSF PGE(2) levels induced by LPS or ET-1 but did not affect the increased hypothalamic PGE(2) levels. Dipyrone also reduced the increase in the venous plasma PGE(2) concentration induced by LPS. CONCLUSIONS AND IMPLICATIONS: These findings confirm that PGE(2) does not play a relevant role in ET-1-induced fever. They also demonstrate for the first time that the antipyretic effect of dipyrone was not mechanistically linked to the inhibition of hypothalamic PGE(2) synthesis.


Subject(s)
Antipyretics/pharmacology , Body Temperature/drug effects , Dinoprostone/biosynthesis , Dipyrone/pharmacology , Fever/drug therapy , Hypothalamus/drug effects , Animals , Cyclooxygenase Inhibitors/pharmacology , Dinoprostone/blood , Dinoprostone/cerebrospinal fluid , Endothelin-1/pharmacology , Escherichia coli , Fever/physiopathology , Hypothalamus/metabolism , Indomethacin/pharmacology , Lipopolysaccharides/pharmacology , Male , Pyrogens/pharmacology , Rats , Rats, Wistar
5.
J Pharm Pharmacol ; 62(2): 205-13, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20487200

ABSTRACT

OBJECTIVES: In the present study we investigated the antinociceptive, anti-inflammatory and antipyretic effects of 7-hydroxycoumarin (7-HC) in animal models. METHODS: The effects of oral 7-HC were tested against acetic acid-induced writhing, formalin test, tail flick test, complete Freund's adjuvant (CFA)-induced hypernociception, carrageenan-induced paw oedema, lipopolysaccharide-induced fever and the rota rod test. KEY FINDINGS: 7-HC (3-60 mg/kg) produced a dose-related antinociception against acetic acid-induced writhing in mice and in the formalin test. In contrast, treatment with 7-HC did not prevent thermal nociception in the tail flick test. A single treatment with 7-HC, 60 mg/kg, produced a long-lasting antinociceptive effect against CFA-induced hypernociception, a chronic inflammatory pain stimulus. Notably, at 60 mg/kg per day over 4 days the administration of 7-HC produced a continuous antinociceptive effect against CFA-induced hypernociception. 7-HC (30-120 mg/kg) produced anti-inflammatory and antipyretic effects against carrageenan-induced inflammation and lipopolysaccharide-induced fever, respectively. Moreover, 7-HC was found to be safe with respect to ulcer induction. In the rota rod test, 7-HC-treated mice did not show any motor performance alterations. CONCLUSIONS: The prolonged antinociceptive and anti-inflammatory effects of 7-HC, in association with its low ulcerogenic activity, indicate that this molecule might be a good candidate for development of new drugs for the control of chronic inflammatory pain and fever.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Inflammation/drug therapy , Pain/drug therapy , Umbelliferones/therapeutic use , Acute Disease , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Chronic Disease , Disease Models, Animal , Dose-Response Relationship, Drug , Edema/drug therapy , Fever/drug therapy , Male , Mice , Motor Activity/drug effects , Pain Measurement , Rats , Rats, Wistar , Umbelliferones/administration & dosage , Umbelliferones/adverse effects , Umbelliferones/pharmacology
6.
Am J Physiol Regul Integr Comp Physiol ; 296(5): R1631-40, 2009 May.
Article in English | MEDLINE | ID: mdl-19244587

ABSTRACT

The present study investigated the febrile response in zymosan-induced arthritis, as well as the increase in PGE(2) concentration in the cerebrospinal fluid (CSF), along with the effects of antipyretic drugs on these responses in rats. Zymosan intra-articularly injected at the dose of 0.5 mg did not affect the body core temperature (Tc) compared with saline (control), whereas at doses of 1 and 2 mg, zymosan promoted a flattened increase in Tc and declined thereafter. The dose of 4 mg of zymosan was selected for further experiments because it elicited a marked and long-lasting Tc elevation starting at 3 1/2 h, peaking at 5 1/2 h, and remaining until 10 h. This temperature increase was preceded by a decrease in the tail skin temperature, as well as hyperalgesia and edema in the knee joint. No febrile response was observed in the following days. In addition, zymosan-induced fever was not modified by the sciatic nerve excision. Zymosan increased PGE(2) concentration in the CSF but not in the plasma. Oral pretreatment with ibuprofen (5-20 mg/kg), celecoxib (1-10 mg/kg), dipyrone (60-240 mg/kg), and paracetamol (100-200 mg/kg) or subcutaneous injection of dexamethasone (0.25-1.0 mg/kg) dose-dependently reduced or prevented the fever during the zymosan-induced arthritis. Celecoxib (5 mg/kg), paracetamol (150 mg/kg), and dipyrone (120 mg/kg) decreased CSF PGE(2) concentration and fever during zymosan-induced arthritis, suggesting the involvement of PGE(2) in this response.


Subject(s)
Analgesics, Non-Narcotic/pharmacology , Arthritis, Experimental/chemically induced , Body Temperature/drug effects , Fever/chemically induced , Zymosan/adverse effects , Acetaminophen/pharmacology , Acetaminophen/therapeutic use , Analgesics, Non-Narcotic/therapeutic use , Animals , Arthritis, Experimental/cerebrospinal fluid , Arthritis, Experimental/drug therapy , Celecoxib , Dexamethasone/pharmacology , Dexamethasone/therapeutic use , Dinoprostone/cerebrospinal fluid , Dipyrone/pharmacology , Dipyrone/therapeutic use , Dose-Response Relationship, Drug , Fever/cerebrospinal fluid , Fever/drug therapy , Ibuprofen/pharmacology , Ibuprofen/therapeutic use , Injections, Intra-Articular , Male , Pyrazoles/pharmacology , Pyrazoles/therapeutic use , Rats , Rats, Wistar , Sulfonamides/pharmacology , Sulfonamides/therapeutic use , Zymosan/administration & dosage
7.
J Pharm Pharmacol ; 58(9): 1265-73, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16945186

ABSTRACT

Lafoensia pacari St. Hil. (Lythraceae) is used in traditional medicine to treat inflammation. Previously, we demonstrated the anti-inflammatory effect that the ethanolic extract of L. pacari has in Toxocara canis infection (a model of systemic eosinophilia). In this study, we tested the anti-inflammatory activity of the same L. pacari extract in mice injected intraperitoneally with beta-glucan present in fraction 1 (F1) of the Histoplasma capsulatum cell wall (a model of acute eosinophilic inflammation). We also determined the anti-oedematous, analgesic and anti-pyretic effects of L. pacari extract in carrageenan-induced paw oedema, acetic acid writhing and LPS-induced fever, respectively. L. pacari extract significantly inhibited leucocyte recruitment into the peritoneal cavity induced by beta-glucan. In addition, the L. pacari extract presented significant analgesic, anti-oedematous and anti-pyretic effects. Bioassay-guided fractionation of the L. pacari extract in the F1 model led us to identify ellagic acid. As did the extract, ellagic acid presented anti-inflammatory, anti-oedematous and analgesic effects. However, ellagic acid had no anti-pyretic effect, suggesting that other compounds present in the plant stem are responsible for this effect. Nevertheless, our results demonstrate potential therapeutic effects of L. pacari extract and ellagic acid, providing new prospects for the development of drugs to treat pain, oedema and inflammation.


Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Ellagic Acid/pharmacology , Lythraceae , Acetic Acid , Analgesics/isolation & purification , Animals , Anti-Inflammatory Agents/isolation & purification , Carrageenan , Edema/chemically induced , Edema/prevention & control , Ellagic Acid/isolation & purification , Female , Fever/chemically induced , Fever/prevention & control , Lipopolysaccharides , Male , Mice , Mice, Inbred BALB C , Pain/chemically induced , Pain/prevention & control , Pain Measurement , Peritonitis/chemically induced , Peritonitis/prevention & control , Plant Bark , Plant Extracts/pharmacology , Plant Stems , Rats , Rats, Wistar , Time Factors , beta-Glucans
8.
Br J Pharmacol ; 146(2): 209-16, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16025141

ABSTRACT

PAF injection into the rat paw is accompanied by the concomitant activation of NF-kappaB and neutrophil influx, which appears to be relevant to the up-regulation of kinin B1 receptors. Herein, we analyse the role of TNF-alpha and IL-1beta production for PAF-induced B1 receptor upregulation in the rat paw. Additionally, we evaluate how cytokine production and neutrophil migration fit into the temporal sequence of events leading to PAF-induced B1 receptor upregulation. In our experiments, treatment with PAF resulted in a marked increase of B1 receptor-mediated paw oedema and in situ production of TNF-alpha at 1 h and IL-1beta at 3 and 6 h later. B1 receptor-mediated paw oedema was significantly inhibited by anti-TNF-alpha antibody and by interleukin-1 receptor antagonist (IRA). TNF-alpha was necessary for the local PAF-induced IL-1beta production. NF-kappaB blocker PDTC prevented the production of both TNF-alpha and IL-1beta, indicating that cytokine production is NF-kappaB dependent. Depletion of neutrophils with an anti-PMN antibody prevented IL-1beta, but not TNF-alpha, production. Although both TNF-alpha and IL-1beta are relevant to functional B1 receptor upregulation, PAF-induced increase in B1 receptor mRNA was markedly suppressed by anti-TNF-alpha and, to a lesser extent, by IRA. B1 receptor mRNA expression was also prevented by the anti-PMN antibody. In conclusion, the activation of the TNF-alpha/neutrophil axis by PAF seems to be sufficient for B1 receptor mRNA production. However, the TNF-alpha/neutrophil axis is also necessary for IL-1beta production. These two processes might lead to the appearance of functional kinin B1 upregulation receptors in vivo after PAF treatment.


Subject(s)
Cytokines/physiology , Neutrophils/physiology , Platelet Activating Factor/pharmacology , Receptor, Bradykinin B1/biosynthesis , Animals , Cytokines/biosynthesis , Edema/pathology , Interleukin-1/biosynthesis , Male , NF-kappa B/biosynthesis , Neutrophil Infiltration/drug effects , Neutrophils/drug effects , Peroxidase/metabolism , RNA, Messenger/biosynthesis , Rats , Rats, Wistar , Time Factors , Tumor Necrosis Factor-alpha/biosynthesis , Up-Regulation/drug effects
9.
Br J Pharmacol ; 135(5): 1107-14, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11877316

ABSTRACT

1. The present study examines the role of migrating leukocytes in the ability of IL-1 beta to induce the functional up-regulation of B(1) receptors, as assessed by kinin B(1) agonist-induced oedema in the rat paw. 2. Pre-treatment with the PAF receptor antagonist WEB 2086 inhibited des-Arg(9)-BK-induced oedema in IL-1 beta-treated paws, while the LTB(4) receptor antagonist CP105696 had no effect. Des-Arg(9)-BK-induced paw oedema was also inhibited by pre-treatment with the selectin blocker fucoidin or by an anti-CD-18 monoclonal antibody. 3. I.d. injection of IL-1 beta produced a 5 - 10-fold increase of myeloperoxidase (MPO) activity in the rat paw. The increase in MPO activity was significantly inhibited by WEB 2086 (46 +/- 9%), fucoidin (68 +/- 5%) or the CD-18 antibody (84 +/- 3%). In contrast, i.d. injection of TNF alpha a dose known to upregulate the B(1) receptor functionally did not induce any significant increase in MPO activity. 4. Des-Arg(9)-BK alone had no effect in MPO activity but enhanced (by about 40%) the response induced by IL-1 beta, an effect prevented by the B(1) receptor antagonist des-Arg(9)-[Leu(8)]-BK. 5. The concentration of TNF-alpha was increased in the paws after i.d. injection of IL-1 beta. Pre-treatment with fucoidin, WEB 2086, anti-CD-18 or CP 105695, significantly reversed the local increases in TNF-alpha concentrations (80 +/- 2; 75 +/- 4, 73 +/- 3 and 40 +/- 2%), respectively. 6. Finally, IL-1 beta induced an increase of B(1) receptor mRNA levels in the rat paw, an effect which was prevented by fucoidin treatment. 7. Taken together, these results indicate that up-regulation of B(1) receptors in the rat paw following IL-1 beta seems to involve the local recruitment of neutrophils and subsequent local TNF-alpha production. The cross-talk between kinins, cytokines and leukocytes implicate B(1) receptors in chronic inflammatory diseases.


Subject(s)
Chemotaxis, Leukocyte/physiology , Interleukin-1/pharmacology , Platelet Membrane Glycoproteins/antagonists & inhibitors , Receptors, Bradykinin/metabolism , Receptors, Cell Surface , Receptors, G-Protein-Coupled , Tumor Necrosis Factor-alpha/metabolism , Up-Regulation , Animals , Bradykinin Receptor Antagonists , Cell Adhesion Molecules , Chemotaxis, Leukocyte/drug effects , Edema/metabolism , Injections, Intradermal , Male , Neutrophils/physiology , Peroxidase/metabolism , RNA, Messenger/analysis , Rats , Rats, Wistar , Receptor Cross-Talk , Receptor, Bradykinin B1 , Receptors, Bradykinin/agonists , Time Factors , Tumor Necrosis Factor-alpha/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...